Author(s):
Anjum Hamid Khan, Laxmikant Purane, Abhirup Sagare, Sanchita Borate, Sunita Wanjale, Prachi Pawar
Email(s):
anjumhkhan8@gmail.com
DOI:
10.52711/2231-5713.2026.00030 
Address:
Anjum Hamid Khan*, Laxmikant Purane, Abhirup Sagare, Sanchita Borate, Sunita Wanjale, Prachi Pawar
Department of Pharmacology, Yashoda Technical Campus, Satara, Dr. Babasaheb Ambedkar Technological University, Lonare 402103, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
In addition to biomarkers with detection tests like ELISA (enzyme-linked immunosorbent assay), diabetes mellitus, gut dysbiosis, an imbalance in gut microbiota, cytokines (IL-6), cytokines (TNF-a), cytokines (IL-10), C-reactive protein (CRP), calprotectin, zonulin, LPS-binding protein, and lipopolysaccharide (LPS). By restoring equilibrium through a variety of substances and plants, including aloe vera, fennel, ginger, dandelion, green tea, etc., as well as phytochemicals like phenols, tannins, flavonoids, curcumin, etc., herbal therapies offer promise modulation. Polyphenols from green tea and aloe vera increase beneficial bacteria like Bifidobacterium, reduce harmful pathogens, strengthen the intestinal barrier, and encourage the production of short-chain fatty acids (SCFAs), according to data from animal studies and clinical assessments. This all-encompassing strategy makes it easier for researchers creating novel herbal medications to cure dysbiosis. Ginger and other tried-and-true herbs are summarized in this article. Celosia cristata, or cockscomb, may satisfy the requirements of dysbiosis by removing or otherwise addressing problems related to the dysbiosis and possessing flavonoids, despite the lack of studies on microbiota alterations, SCFAs, or gut barrier models. This study does not test this plant. This author has started a new study (ongoing work) using floral extracts to close the gap.
Cite this article:
Anjum Hamid Khan, Laxmikant Purane, Abhirup Sagare, Sanchita Borate, Sunita Wanjale, Prachi Pawar. A review on Dysbiosis: Diagnosis, Biomarker Identification, and Herbal Therapies, Celosia Cristata. Asian Journal of Pharmacy and Technology. 2026; 16(2):207-8. doi: 10.52711/2231-5713.2026.00030
Cite(Electronic):
Anjum Hamid Khan, Laxmikant Purane, Abhirup Sagare, Sanchita Borate, Sunita Wanjale, Prachi Pawar. A review on Dysbiosis: Diagnosis, Biomarker Identification, and Herbal Therapies, Celosia Cristata. Asian Journal of Pharmacy and Technology. 2026; 16(2):207-8. doi: 10.52711/2231-5713.2026.00030 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-2-15
REFERENCES:
1. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014 Jul; 16(7): 1024–1033. doi:10.1111/cmi.12308. PMID: 24697914; PMCID: PMC4143175. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4143175/
2. Carías Domínguez AM, Rosa Salazar DJ, Stefanolo JP, Cruz Serrano MC, Casas IC, Zuluaga Peña JR. Intestinal dysbiosis: exploring definition, associated symptoms, and perspectives for comprehensive understanding scoping review. Probiotics Antimicrobe Proteins. 2025; 17: 440–449 doi:10.1007/s12602-024-10353-w.
3. Lin TY, Wu PH, Lin YT, Hung SC. Gut dysbiosis and mortality in hemodialysis patients. NPJ Biofilms Microbiomes. 2021 Dec 1;7(1). Available from: https://pubmed-ncbi-nlm-nih-gov.udea.lookproxy.com/33658514/
4. Bidell MR, Hobbs ALV, Lodise TP. Gut microbiome health and dysbiosis: a clinical primer. Pharmacotherapy. 2022 Nov 1; 42(1): 849–857. Available from: https://pubmed-ncbi-nlm-nih-gov.udea.lookproxy.com/36168753/
5. Luca M, Chattipakorn SC, Sriwichaiin S, Luca A. Cognitive-behavioral correlates of dysbiosis: a review. Int J Mol Sci. 2020 Jul 2; 21(14): 1–14. Available from: https://pubmed-ncbi-nlm-nih-gov.udea.lookproxy.com/32650553/
6. Wallace RK. The microbiome in health and disease from the perspective of modern medicine and Ayurveda. Medicina. 2020; 56:462. doi:10.3390/medicina56090462
7. Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature. 2019; 569: 641–648. doi:10.1038/s41586-019-1238-8
8. Karakasidis E, Kotsiou OS, Gourgoulianis KI. Lung and gut microbiome in COPD. J Pers Med. 2023; 13: 804. doi:10.3390/jpm13050804
9. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The role of lung and gut microbiota in the pathology of asthma. Immunity. 2020; 52:241–255. doi: 10.1016/j.immuni.2020.01.007
10. Janowski A, Newland J. From the microbiome to the central nervous system: an update on the epidemiology and pathogenesis of bacterial meningitis in childhood. F1000Res. 2017; 6: F1000 Faculty Rev-86. doi:10.12688/f1000research.8533.1
11. Kim JE, Kim HS. Microbiome of the skin and gut in atopic dermatitis (AD): understanding the pathophysiology and finding novel management strategies. J Clin Med. 2019; 8: 444. doi:10.3390/jcm8040444
12. Siljander H, Honkanen J, Knip M. Microbiome and type 1 diabetes. EBioMedicine. 2019; 46: 512–521. doi: 10.1016/j.ebiom.2019.06.031
13. Casén C, Vebø HC, Sekelja M, Hegge FT, Karlsson MK, Ciemniejewska E, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015 Jul; 42(1): 71–83. doi:10.1111/apt.13236. Epub 2015 May 13. PMID: 25959883; PMCID: PMC5029765
14. Tynkkynen T, Wang Q, Ekholm J, Anufrieva O, Ohukainen P, Vepsäläinen J, et al. Proof of concept for quantitative urine NMR metabolomics pipeline for large-scale epidemiology and genetics. Int J Epidemiol. 2019; 48: 978–993. doi:10.1093/ije/dyy287
15. Ribeiro WR, Vinolo M, Calixto LR, Ferreira CM. Use of gas chromatography to quantify short-chain fatty acids in the serum, colonic luminal content, and feces of mice. Bio Protoc. 2018; 8: e3089. doi:10.21769/BioProtoc.3089
16. Rana SV, Malik A. Hydrogen breath tests in gastrointestinal diseases. Indian J Clin Biochem. 2014; 29: 398–405. doi:10.1007/s12291-014-0426-4
17. Blue Cross Blue Shield Association Evidence Positioning System®. 2.04.26—Fecal analysis in the diagnosis of intestinal dysbiosis. 01/202.
18. Jeffery IB, Das A, O’Herlihy E, et al. Differences in fecal microbiomes and metabolomes of people with vs. without irritable bowel syndrome and bile acid malabsorption. Gastroenterology. 2020; 158:1016–1028.e8. doi: 10.1053/j.gastro.2019.11.301
19. Tang Q, Jin G, Wang G, Liu T, Liu X, Wang B, et al. Current sampling methods for gut microbiota: a call for more precise devices. Front Cell Infect Microbiol. 2020; 10: 1–10. doi:10.3389/fcimb.2020.00151
20. Li Z, Zhou J, Liang H, Ye L, Lan L, Lu F, et al. Differences in alpha diversity of gut microbiota in neurological diseases. Front Neurosci. 2022; 16: 879318. doi:10.3389/fnins.2022.879318
21. Terrón-Camero LC, Gordillo-González F, Salas-Espejo E, Andrés-León E. Comparison of metagenomics and metatranscriptomics tools: a guide to making the right choice. Genes. 2022; 13: 2280. doi:10.3390/genes13122280
22. Wei S, Bahl MI, Baunwall SMD, Hvas CL, Licht TR. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021; 87: e00395–21. doi:10.1128/AEM.00395-21
23. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012; 336:1262–1267. doi:10.1126/science.1223813
24. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007; 26: 51–78. doi:10.1002/mas.20108
25. Wu WK, Chen CC, Liu PY, Panyod S, Liao BY, Chen PC, et al. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut. 2019; 68: 1439–1449. doi:10.1136/gutjnl-2018-317155
26. Musa MA, Kabir M, Hossain MI, Ahmed E, Siddique A, Rashid H, et al. Measurement of intestinal permeability using lactulose and mannitol with conventional five-hour and shortened two-hour urine collection by two different methods: HPAE-PAD and LC-MSMS. PLoS One. 2019; 14: e0220397. doi: 10.1371/journal.pone.0220397
27. Rüb AM, Di Domenico M, Gschwind R, et al. Biomarkers of human gut microbiota diversity and dysbiosis. Biomark Med. 2021 Feb; 15(2): 137–148. doi:10.2217/bmm-2020-0353. Epub 2021 Jan 14. PMID: 33442994. Available from: https://pubmed.ncbi.nlm.nih.gov/33442994/
28. Sivaprakasam S, Heinken A, Brunk E, et al. Biomarker quantification of gut dysbiosis-derived inflammation: a review. J Inflamm Res. 2025 Oct 21; 18: 14551–14567. doi:10.2147/JIR.S539155. PMID: 41140744; PMCID: PMC12553352. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12553352/
29. Kasar GN, et al. Navigating dysbiosis: insights into gut microbiota disruption and therapeutic interventions. Clin Adv Integr Med. 2025 Jun 19. Available from: https://www.hksmp.com/journals/cai/article/view/778
30. Sivaprakasam S, Heinken A, Brunk E, et al. Biomarker quantification of gut dysbiosis-derived inflammation: a review. J Inflamm Res. 2025; 18: 14551–14567. doi:10.2147/JIR.S539155. PMID: 41140744; PMCID: PMC12553352. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12553352/
31. Heinken A, et al. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021 Mar 18; 87(7): e00395–21. doi:10.1128/AEM.00395-21. Available from: https://journals.asm.org/doi/10.1128/aem.00395-21
32. Safarchi A, et al. Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challenges. Front Microbiol. 2025 Mar 3; 16: 1559521. doi:10.3389/fmicb.2025.1559521. Available from: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1559521/full
33. Bencardino S, D’Amico F, Zilli A, et al. Fecal, blood, and urinary biomarkers in inflammatory bowel diseases. J Transl Gastroenterol. 2024;2(2):61–75
34. Brown EL, Essigmann HT, Hoffman KL, et al. C-reactive protein levels correlate with measures of dysglycemia and gut microbiome profiles. Curr Microbiol. 2024; 81(1): 45
35. Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczyńska M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol. 2019;66(1):1–12. doi:10.18388/abp.2018_2648
36. Huang W, Zhou L, Guo H, Xu Y, Xu Y. The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response. Metabolism. 2017; 68: 20-30. doi: 10.1016/j.metabol.2016.11.006. PMID: 28183450.
37. Síbia C, Quaglio AE, Oliveira EC, et al. microRNA–mRNA networks linked to inflammation and immune system regulation in inflammatory bowel disease. Biomedicines. 2024; 12(2): 422. doi:10.3390/biomedicines12020422
38. Molinaro A, Bel Lassen P, Henricsson M, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun. 2020;11(1):5881. doi:10.1038/s41467-020-19589-w
39. Koh A, Mannerås-Holm L, Yunn N-O, et al. Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylation. Cell Metab. 2020; 32(4): 643–653.e4. doi: 10.1016/j.cmet.2020.07.012
40. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: the good, the bad, and the unknown. Toxins. 2016; 8(11): 326. doi:10.3390/toxins8110326
41. Constantino-Jonapa LA, Espinoza-Palacios Y, Escalona-Montaño AR, et al. Contribution of trimethylamine N-oxide (TMAO) to chronic inflammatory and degenerative diseases. Biomedicines. 2023; 11(2): 431. doi:10.3390/biomedicines11020431
42. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011; 91(1): 151–175. doi:10.1152/physrev.00003.2008
43. Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. FResearch. 2020;9
44. Brown EL, Essigmann HT, Hoffman KL, et al. C-reactive protein levels correlate with measures of dysglycemia and gut microbiome profiles. Curr Microbiol. 2024; 81(1): 45
45. Camacho V, McClearn V, Patel S, Welner RS. Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment. Int J Hematol. 2017; 105(5): 566–577. doi:10.1007/s12185-017-2184-6
46. Leppkes M, Roulis M, Neurath MF, Kollias G, Becker C. Pleiotropic functions of TNF-α in the regulation of the intestinal epithelial response to inflammation. Int Immunol. 2014; 26(9): 509–515. doi:10.1093/intimm/dxu051
47. Burrello C, Garavaglia F, Cribiù FM, et al. Therapeutic fecal microbiota transplantation controls intestinal inflammation through IL-10 secretion by immune cells. Nat Commun. 2018;9(1):5184. doi:10.1038/s41467-018-07359-8
48. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Adv Sci. 2021; 8(15): 2004433. doi:10.1002/advs.202004433
49. Hug H, Mohajeri MH, La Fata G. Toll-like receptors: regulators of the immune response in the human gut. Nutrients. 2018; 10(2): 203. doi:10.3390/nu10020203
50. Burgueño JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17(5):263–278. doi:10.1038/s41575-019-0261-4
51. Rhee SH. Lipopolysaccharide: basic biochemistry, intracellular signaling, and physiological impacts in the gut. Intest Res. 2014; 12(2): 90–95. doi:10.5217/ir.2014.12.2.90
52. Roy R, Kumar D, Bhattacharya P, Borah A. Modulating the biosynthesis and TLR4-interaction of lipopolysaccharide as an approach to counter gut dysbiosis and Parkinson’s disease: the role of phyto-compounds. Neurochem Int. 2024; 178: 105803. doi: 10.1016/j.neuint.2024.105803
53. Hersoug LG, Møller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 2016; 17(4): 297–312. doi:10.1111/obr.12370
54. Phalipon A, Cardona A, Kraehenbuhl J-P, Edelman L, Sansonetti PJ, Corthésy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity. 2002; 17(1): 107–115. doi:10.1016/S1074-7613(02)00341-2
55. Goguyer-Deschaumes R, Waeckel L, Killian M, Rochereau N, Paul S. Metabolites and secretory immunoglobulins: messengers and effectors of the host–microbiota intestinal equilibrium. Trends Immunol. 2022; 43(1): 63–77. doi:10.1016/j.it.2021.11.005
56. Huang W-Q, Huang H-L, Peng W, et al. Altered pattern of immunoglobulin A-targeted microbiota in inflammatory bowel disease after fecal transplantation. Front Microbiol. 2022; 13: 873018. doi:10.3389/fmicb.2022.873018
57. Kasar GN, Rasal PB, Upaganlawar AB, Pagar DS, Surana KR, Mahajan SK, Sonawane DD. Navigating dysbiosis: insights into gut microbiota disruption and therapeutic interventions. Clin Adv Integr Med. 2025 Jun 19; [Epub ahead of print]. Available from: https://www.hksmp.com/journals/cai/article/view/778
58. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021; 19(1): 55–71. doi:10.1038/s41579-020-0433-9
59. Guan Y, Tang G, Li L, Shu J, Zhao Y, Huang L, Tang J. Herbal medicine and gut microbiota: exploring untapped therapeutic potential in neurodegenerative disease management. Arch Pharm Res. 2024; 47: 146–164. doi:10.1007/s12272-023-01484-9
60. 61. Xia Y, Chen Y, Wang Q, et al. Modulation of gut microbiota by herbal medicine enhancing diversity. Front Pharmacol. 2022; 13:942911. doi:10.3389/fphar.2022.942911.
61. Zhang Y, Liu X, Guo S, et al. Herbal medicine modulates gut microbiota in obesity and type 2 diabetes. Front Endocrinol (Lausanne). 2021; 12:656497. doi:10.3389/fendo.2021.656497.
62. Boudreau MD, Beland FA. An evaluation of the biological and toxicological properties of Aloe barbadensis (miller), aloe vera. J Environ Sci Health C Environ Carcinogen Ecotoxicol Rev. 2006; 24(1): 103-54. doi:10.1080/10408440600550912.
63. Liu C, Du P, Guo Y, et al. Extraction, characterization of aloe polysaccharides, and the in-depth analysis of its prebiotic effects on mice gut microbiota. Carbohydr Polym. 2021; 261: 117874. doi: 10.1016/j.carbpol.2021.117874.
64. Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of hydroxy anthracene derivatives for use in food. EFSA J. 2018; 16(1): 5090. doi: 10.2903/j.efsa.2018.5090.
65. Pop RM, Puia IC, Puia A, et al. Aloe vera gel—a natural source of antioxidants. Not Bot Horti Agrobo. 2022; 50(1): 12732. doi:10.15835/nbha50112732.
66. Chiodelli G, Pellizzoni M, Ruzickova G, Lucini L. Effect of different aloe fractions on the growth of lactic acid bacteria. J Food Sci. 2017; 82(1): 219-24. doi:10.1111/1750-3841.13609.
67. Cellini L, Di Bartolomeo S, Di Campli E, et al. In vitro activity of Aloe vera inner gel against Helicobacter pylori strains. Lett Appl Microbiol. 2014;59(1):43-8. doi:10.1111/lam.12293.
68. Hong SW, Chun J, Park S, et al. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Neurogastroenterol Motil. 2018;24(4):528-35. doi:10.5056/jnm18022.
69. Ahluwalia B, Magnusson MK, Böhn L, et al. Aloe barbadensis Mill. extract improves symptoms in IBS patients with diarrhea: post hoc analysis of two randomized double-blind controlled studies. Therap Adv Gastroenterol. 2021; 14:17562848211048133. doi:10.1177/17562848211048133.
70. Epure A, Pârvu A, Vlase L, et al. Polyphenolic compounds, antioxidant activity, and nephroprotective properties of Romanian Taraxacum officinale. Farmacia. 2022;70(1):47-53. doi:10.31925/farmacia.2022.1.7.
71. Jalili C, Abbasi A, Rahmani-Kukia N, et al. The relationship between aflatoxin B1 with the induction of extrinsic/intrinsic pathways of apoptosis and the protective role of taraxasterol in the TM3 Leydig cell line. Ecotoxicol Environ Saf. 2024; 276:116316. doi: 10.1016/j.ecoenv.2024.116316.
72. Ge B, Sang R, Wang W, et al. Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in vitro and in vivo experiments. Phytomedicine. 2023; 116: 154872. doi: 10.1016/j.phymed.2023.154872.
73. Ionescu D, Predan G, Rizea GD, et al. antimicrobial activity of some hydroalcoholic extracts of artichoke (Cynara scolymus), burdock (Arctium lappa), and dandelion (Taraxacum officinale). For Wood Ind Agric Food Eng. 2013; 6:113-20.
74. Okafor IA, Okafor US. The methanolic extract of Zingiber officinale causes hypoglycemia and a proinflammatory response in the rat pancreas. Physiol Pharmacol. 2022; 26(4): 433-9.
75. Dugasani S, Pichika MR, Nadarajah VD, et al. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol, and [6]-shogaol. J Ethnopharmacol. 2010; 127(2): 515-20. doi: 10.1016/j.jep.2009.10.004.
76. Iwami M, Shiina T, Hirayama H. Inhibitory effects of zingerone, a pungent component of Zingiber officinale Roscoe, on colonic motility in rats. J Nat Med. 2011; 65(1): 89-94. doi:10.1007/s11418-010-0460-6.
77. Iwami M, Shiina T, Hirayama H, Shimizu Y. Intraluminal administration of zingerol, a non-pungent analogue of zingerone, inhibits colonic motility in rats. Biomed Res. 2011; 32(3): 181-5. doi:10.2220/biomedres.32.181.
78. Syed ZA, Fahim A, Safdar M, et al. Role of ginger in management of nausea among patients receiving chemotherapy. Pak J Med Sci. 2024; 40(6): 2036. doi:10.12669/pjms.40.6.5164.
79. Beristain-Bauza SDC, Hernández-Carranza P, Cid-Pérez TS, et al. antimicrobial activity of ginger (Zingiber officinale) and its application in food products. Food Rev Int. 2019; 35(5): 407-26. doi:10.1080/87559129.2019.1579828.
80. Elfaky MA, Okairy HM, Abdallah HM, et al. Assessing the antibacterial potential of 6-gingerol: combined experimental and computational approaches. Saudi Pharm J. 2024; 32(2): 102041. doi: 10.1016/j.jsps.2024.102041.
81. Mohamed ME, Kandeel M, El-Lateef HMA, et al. The protective effect of anethole against renal ischemia/reperfusion: the role of the TLR2/4/MYD88/NF-κB pathway. Antioxidants (Basel). 2022; 11(3): 535. doi:10.3390/antiox11030535.
82. Kwiatkowski P, Wojciuk B, Wojciechowska-Koszko I, et al. Innate immune response against Staphylococcus aureus preincubated with subinhibitory concentration of trans-anethole. Int J Mol Sci. 2020; 21(12): 4178. doi:10.3390/ijms21124178.
83. Korinek M, Handoussa H, Tsai YH, et al. Anti-inflammatory and antimicrobial volatile oils: fennel and cumin inhibit neutrophilic inflammation via regulating calcium and MAPKs. Front Pharmacol. 2021; 12:674095. doi:10.3389/fphar.2021.674095.
84. Malhotra SK. Fennel and fennel seed. In: Handbook of herbs and spices. 2nd ed. Cambridge: Woodhead Publishing; 2012. p. 275-302.
85. Lee JH, Lee DU, Kim YS, Kim HP. 5-Lipoxygenase inhibition of the fructus of Foeniculum vulgare and its constituents. Biomol Ther (Seoul). 2012; 20(1): 113-7. doi:10.4062/biomolther.2012.20.1.113.
86. Mechraoui I, Mahfoudi R, Djeridane A, et al. Comparative chemical profiling and antioxidant properties of essential oils extracted from Foeniculum vulgare subsp. piperitum. Biocatal Agric Biotechnol. 2024; 60: 103306. doi: 10.1016/j.bcab.2024.103306.
87. Saddiqi HA, Iqbal Z. Usage and significance of fennel (Foeniculum vulgare Mill.) seeds in Eastern medicine. In: Nuts and seeds in health and disease prevention. Amsterdam: Elsevier; 2011. p. 461-7.
88. Sayah K, El Omari N, Kharbach M, et al. Comparative study of leaf and rootstock aqueous extracts of Foeniculum vulgare on chemical profile and in vitro antioxidant and antihyperglycemic activities. Adv Pharmacol Pharm Sci. 2020; 2020: 8852570. doi:10.1155/2020/8852570.
89. Lee JH, Lee DU, Kim YS, Kim HP. 5-Lipoxygenase inhibition of the fructus of Foeniculum vulgare and its constituents. Biomol Ther (Seoul). 2012; 20(1): 113-7. doi:10.4062/biomolther.2012.20.1.113.
90. Capasso L, De Masi L, Sirignano C, Maresca V, Nebbioso A, Rigano D, et al. Epigallocatechin gallate (EGCG): pharmacological properties, biological activities, and therapeutic potential. Molecules. 2025;30(3):654. doi:10.3390/molecules30030654.
91. Joseph S, Nallaswamy D, Rajeshkumar S, Dathan P, Ismail S, Jacob J, et al. A glimpse through the origin, composition, and biomedical applications of green tea and its polyphenols: a review. Plant Sci Today. 2024; 11(3): 330-41. doi:10.14719/pst.2024.11.3.1936.
92. Dong XW. Epigallocatechin-gallate: unraveling its protective mechanisms and therapeutic potential. Cell Biochem Funct. 2025; 43(2): e70056. doi:10.1002/cbf.70056.
93. Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008; 269(2): 269-80. doi: 10.1016/j.canlet.2008.03.019.
94. Rashidinejad A, Boostani S, Babazadeh A, Rehman A, Rezaei A, Akbari-Alavi Jeh S. Opportunities and challenges for the nano delivery of green tea catechins in functional foods. Food Res Int. 2021; 142:110186. doi: 10.1016/j.foodres.2021.110186
95. Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006; 67(16): 1849-55. doi: 10.1016/j.phytochem.2006.06.020.
96. Dang S, Gupta S, Bansal R, Ali J, Gabrani R. Nano-encapsulation of a natural polyphenol, green tea catechins: a way to preserve its antioxidative potential. In: Kurakane S, Wada S, eds. Free radicals in human health and disease. New Delhi: Springer; 2015. p. 397-415.
97. Mehmood S, Maqsood M, Mahtab N, Issa M, Sahar A, Zaib S, et al. Epigallocatechin gallate: phytochemistry, bioavailability, utilization challenges, and strategies. J Food Biochem. 2022; 46(5): e1418. doi:10.1111/jfbc.1418.
98. da Silva Pinto M. Tea: a new perspective on health benefits. Food Res Int. 2013; 53(2): 558-67. doi: 10.1016/j.foodres.2013.01.038.
99. Luo Q, Luo L, Zhao J, Wang Y, Luo H. Biological potential and mechanisms of tea's bioactive compounds: an updated review. J Adv Res. 2024; 65: 345-63. doi: 10.1016/j.jare.2024.01.012.
100. Reygaert WC. Green tea catechins: their use in treating and preventing infectious diseases. Biomed Res Int. 2018; 2018: 9105261. doi:10.1155/2018/9105261.
101. Molan AL, Flanagan J, Wei W, Moughan PJ. Selenium-containing green tea has higher antioxidant and prebiotic activities than regular green tea. Food K 2009; 114(3): 829-35. doi: 10.1016/j.foodchem.2008.10.028.
102. Kalam MA, Jan U, Bhat AA, Ashraf B. Main phytochemical Sarwālī (Celosia cristata): medicinal importance in the perspective of Unani medicine and pharmacological studies. J Complement Altern Med Res. 2024; 25(2): 516. doi:10.9734/JOCAMR/2024/v25i2516
103. Santhiravel S, Bekhit AED, Mendis E, Jacobs JL, Dunshea FR, Rajapakse N, et al. The impact of plant phytochemicals on the gut microbiota of humans for a balanced life. Nutrients. 2022;14(14):2932. doi:10.3390/nu14142932.
104. Dias MC, Pinto DCGA, Silva AMS. Plant flavonoids: chemical characteristics and biological activity. Molecules. 2021; 26(17): 5377. doi:10.3390/molecules26175377.
105. Holma R, Kekkonen RA, Hatakka K, Poussa T, Vapaatalo H, Adlercreutz H, et al. Low serum enterolactone concentration is associated with low colonic Lactobacillus-Enterococcus counts in men but is not affected by a synbiotic mixture in a randomized, placebo-controlled, double-blind, crossover intervention study. Br J Nutr. 2014; 111(2): 301-9. doi:10.1017/S0007114513002467
106. Corona G, Kreimes A, Barone M, Turroni S, Brigidi P, Keleszade E, et al. Impact of lignans in oilseed mix on gut microbiome composition and enterolignan production in younger healthy and premenopausal women: an in vitro study. Microb Cell Fact. 2020; 19(1): 82. doi:10.1186/s12934-020-01330-0.
107. Rinninella E, Mele MC, Merendino N, Cintoni M, Anselmi G, Caporossi A, et al. The role of diet, micronutrients, and the gut microbiota in age-related macular degeneration: new perspectives from the gut-retina axis. Nutrients. 2018; 10(11): 1677. doi:10.3390/nu10111677.
108. Lyu Y, Wu L, Wang F, Shen X, Lin D. Carotenoid supplementation and retinoic acid in immunoglobulin A regulation of the gut microbiota dysbiosis. Exp Biol Med (Maywood). 2018; 243(8): 613-20. doi:10.1177/1535370217751339.
109. Palczewski G, Widjaja-Adhi MAK, Amengual J, Olczak M, von Linting J. Genetic dissection in a mouse model reveals interactions between carotenoids and lipid metabolism. J Lipid Res. 2016;57(9):1684-95. doi:10.1194/jlr.M067983
110. Bohn T. Bioactivity of carotenoids—chasms of knowledge. Int J Vitam Nutr Res. 2017; 87(3-4): 5-9. doi: 10.1024/0300-9831/a000455.
111. Ohno M, Nishida A, Sugitani Y. Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. PLoS One. 2017;12(10): e0185999. doi: 10.1371/journal.pone.0185999.
112. McFadden RM, Larmonier CB, Shehab KW. The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis. 2015; 21(11): 2483-94. doi: 10.1097/MIB.0000000000000512.
113. Feng W, Wang H, Zhang P. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. Biochim Biophys Acta Mol Basis Dis. 2017; 1861(8): 1801-12. doi: 10.1016/j.bbadis.2017.05.011
114. Bereswill S, Munoz M, Fischer A. Anti-inflammatory effects of resveratrol, curcumin, and simvastatin in acute small intestinal inflammation. PLoS One. 2010; 5(12): e15099. doi: 10.1371/journal.pone.0015099.
115. Kumar N, Goel N. Phenolic acids: natural versatile molecules with promising therapeutic applications. Biotechnol Rep (Amst). 2019; 24: e00370. doi: 10.1016/j.btre. 2019.e00370.
116. Juurlink BH, Azouz HJ, Aldalati AM, AlTinawi BM, Ganguly P. Hydroxybenzoic acid isomers and the cardiovascular system. Nutr J. 2014; 13: 63. doi:10.1186/1475-2891-13-63.
117. Yadav E. Protective effect of protocatechuic acid-rich fraction of Trianthema portulacastrum against collagen-induced rheumatoid arthritis via gut microbiota modulation. Ann Rheum Dis. 2019; 78(Suppl 2): 1098
118. Wang Y, Wang Y, Wang B, Mei X, Jiang S, Li W. Protocatechuic acid improved growth performance, meat quality, and intestinal health of Chinese yellow-feathered broilers. Poult Sci. 2019; 98(7): 3138-49. doi:10.3382/PS/pez091.
119. El-Seedi HR, El-Said AMA, Khalifa SAM, Göransson U, Bohlin L, Borg-Karlson AK. Biosynthesis, natural sources, dietary intake, pharmacokinetic properties, and biological activities of hydroxycinnamic acids. J Agric Food Chem. 2012; 60(44): 10877-95. doi:10.1021/jf300830s.
120. Hassanpour S, Maheri-Sis N, Eshratkhah B, Mehmandar FB. Plants and secondary metabolites (tannins): a review. Int J For Soil Eros. 2011; 1(1): 47-53.
121. Bialonska D, Kasimsetty SG, Schrader KK, Ferreira D. The effect of pomegranate (Punica granatum L.) byproducts and ellagitannins on the growth of human gut bacteria. J Agric Food Chem. 2009; 57(18): 8344-9. doi: 10.1021/jf901782y.
122. Bialonska D, Ramnani P, Kasimsetty SG, Muntha KR, Gibson GR, Ferreira D. The influence of pomegranate by-products and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol. 2010; 140(2-3): 175-82. doi: 10.1016/j.ijfoodmicro.2010.04.011.
123. Larrosa M, González-Sarrías A, Yáñez-Gascón MJ, Selma MV, Azorín-Ortuño M, Toti S, et al. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem. 2010; 21(8): 717-25. doi: 10.1016/j.jnutbio.2009.04.016.
124. Li Z, Henning SM, Lee RP, Lu QY, Summanen PH, Thames G, et al. Pomegranate extract induces metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 2015; 6(8): 2487-95. doi:10.1039/c5fo00325a.
125. Samanta S, Giri S, Parua S, Nandi DK, Pati BR, Mondal KC. Impact of tannic acid on the gastrointestinal microflora. Microb Ecol Health Dis. 2004; 16(1): 32-4. doi:10.1080/08910600410023211.
126. Smith AH, Mackie RI. Effect of condensed tannins on bacterial diversity and metabolic activity in the rat gastrointestinal tract. Appl Environ Microbiol. 2004; 70(2): 1104-15. doi: 10.1128/AEM.70.2.1104-1115.2004.
127. Massot-Cladera M, Pérez-Berezo T, Franch A, Castell M, Pérez-Cano FJ. Cocoa's modulatory effect on rat fecal microbiota and colonic crosstalk. Arch Biochem Biophys. 2012; 527(2): 105-12. doi: 10.1016/j.abb.2012.05.018.
128. Lin L, George J, Liu G. Biomarker quantification of gut dysbiosis-derived inflammation: a review. J Inflamm Res. 2025; 18: 14551-67. doi:10.2147/JIR.S539155.